Drug Trial Radar · NCT00853658
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
Last checked: Nov 19, 2026Latest source record: Nov 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,064
Actual
Start
Mar 2009
Primary completion
Oct 2015
Study completion Oct 2015
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 2, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV.
Conditions
- Chronic Heart Failure
Interventions
EnalaprilDrug
Enalapril 10 mg film-coated tablet and administered orally.
AliskirenDrug
Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) HospitalizationTime frame: up to End of Study (78 months)
Locations
806 sites in 44 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Huntsville, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Hot Springs, Arkansas
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Pine Bluff, Arkansas
Novartis Investigative Site
Searcy, Arkansas
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
French Camp, California
Novartis Investigative Site
Inglewood, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Modesto, California
Novartis Investigative Site
Northridge, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
Santa Monica, California
Novartis Investigative Site
Westlake Village, California
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Littleton, Colorado
Novartis Investigative Site
Boynton Beach, Florida
Novartis Investigative Site
Daytona Beach, Florida
Novartis Investigative Site
Fort Lauderdale, Florida
Novartis Investigative Site
Hollywood, Florida
Novartis Investigative Site
Jacksonville Beach, Florida
Novartis Investigative Site
Miami Lakes, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Wellington, Florida
Novartis Investigative Site
Athens, Georgia
Novartis Investigative Site
Augusta, Georgia
Novartis Investigative Site
Gillespie, Illinois
Novartis Investigative Site
Topeka, Kansas
Novartis Investigative Site
Metairie, Louisiana
Novartis Investigative Site
New Orleans, Louisiana
Novartis Investigative Site
Slidell, Louisiana
Novartis Investigative Site
Auburn, Maine
Novartis Investigative Site
Southfield, Michigan
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Lincoln, Nebraska
Showing 40 of 806 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.